Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

February 26, 2018February 26, 2018

EMA’s CHMP Recommends Lynparza as Maintenance Therapy for Platinum-sensitive Ovarian Cancer

News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that Lynparza (olaparib) be approved to prevent disease progression and relapse in ovarian cancer patients who responded to platinum-based ... Read more

February 16, 2018February 16, 2018

Early Access to Palliative Care Improves Quality of Life of Terminal Cancer Patients

News

Early access to palliative care significantly enhances the quality of life of advanced cancer patients in their final stages, British researchers reported. Palliative care focuses on the whole person, not ... Read more

February 5, 2018

First Patient Dosed in Phase 3 Trial Testing VB-111 in Platinum-resistant Ovarian Cancer

News

VBL Therapeutics has successfully administered the initial dose to the first patient in its Phase 3 trial investigating the effects of VB-111 (ofranergene obadenovec) in platinum-resistant ovarian cancer. The pivotal OVAL ... Read more

January 26, 2018

Genetic Testing for All Older Than 30 Would Prevent Many Ovarian and Breast Cancers, Study Says

News

Researchers argue in a new study that all women older than 30 should undergo screening for mutations in established risk genes for breast and ovarian cancer. Such a strategy, they ... Read more

January 22, 2018

New Test Detects Ovarian, 7 Other Cancers Using Simple Blood Sample

News

Ovarian cancer detection may become easier and without an expensive bill attached as researchers developed the first test that screens for this and seven other common cancer types using a simple ... Read more

January 15, 2018

Celsion to Initiate Phase 1/2 Trial of GEN-1 in Newly-diagnosed Ovarian Cancer Patients

News

A Phase 1/2 trial to evaluate the DNA-based immunotherapy GEN-1 in patients with newly-diagnosed advanced ovarian cancer has been cleared by the U.S. Food and Drug Administration (FDA) without restrictions, Celsion announced. Recruitment ... Read more

December 22, 2017December 22, 2017

Phase 1 Study Showing COTI-2 Safe in Potentially Treating Advanced Ovarian and Other Cancers

News

Initial data from an early clinical trial in patients with advanced ovarian and other cancers found a potential oral therapy, COTI-2, to be safe at varying doses, supporting a more advanced ... Read more

December 20, 2017

Tesaro’s Zejula for Recurrent Ovarian Cancer Now Available in Germany

News

Zejula (niraparib), an oral therapy for patients with recurrent ovarian cancer, is now available in Germany, according to Tesaro, the biopharma that developed the therapy. “The introductions of Zejula in Germany and ... Read more

December 13, 2017

First Recurrent Ovarian Cancer Patient Dosed with FATE-NK100 in APOLLO Trial

News

The first ovarian cancer patient in the APOLLO Phase 1 clinical trial has been dosed with FATE-NK100, Fate Therapeutics‘ investigational NK (natural killer) cell therapy. The Phase 1 trial (NCT03213964), which ... Read more

November 1, 2017November 1, 2017

Propanc Biopharma Seeks Orphan Drug Status for PRP, Its Lead Product for Ovarian Cancer Treatment

News

Propanc Biopharma has submitted an orphan drug designation request to the U.S. Food and Drug Administration (FDA) for PRP, its lead product for treatment of ovarian cancer. PRP is an intravenous ... Read more